PMID- 28745079 OWN - NLM STAT- MEDLINE DCOM- 20180522 LR - 20240313 IS - 2058-7384 (Electronic) IS - 0394-6320 (Print) IS - 0394-6320 (Linking) VI - 30 IP - 3 DP - 2017 Sep TI - Cytokine production in mammary adenocarcinoma and its microenvironmental cells in patients with or without metastases in regional lymph nodes. PG - 308-314 LID - 10.1177/0394632017720055 [doi] AB - In recent years, the concept of formation of a sufficiently autonomous cytokine network in a malignant tumour has emerged. In this regard, the data on the role of this network and its signalling pathways in the process of metastasis are an interesting topic. The aim of this study was to evaluate the in vitro cytokine-producing potential of mammary adenocarcinoma (MAC; and cells of its microenvironment) from patients with or without metastases in regional lymph nodes (LNs). By enzyme-linked immunosorbent assays of culture supernatants, we studied the cytokine production by biopsy samples of MAC: spontaneous and stimulated by polyclonal activators (PAs: phytohaemagglutinin, concanavalin A and lipopolysaccharide). The levels of spontaneous production of interleukin (IL)-10 and granulocyte colony-stimulating factor (G-CSF) and the amounts of IL-2, IL-10, G-CSF and monocyte chemoattractant protein-1 (MCP-1) produced during stimulation by PAs, as well as the index of stimulation by polyclonal activators (ISPA) for IL-2 production, were lower for MAC with LN metastasis than for MAC without LN metastasis. The levels of spontaneous production of IL-2 and interferon (IFN)-gamma and the ISPA for granulocyte-macrophage colony-stimulating factor (GM-CSF) production were higher for MAC with LN metastasis. There were only three pairwise correlations between the produced cytokines that were specific to MAC with LN metastasis: IL-2 and IFN-gamma, IL-6 and GM-CSF, and IL-8 and GM-CSF. There were 10 pairwise correlations between the produced cytokines that were specific to nonmetastasising MAC: IL-6 and IL-10, IL-6 and MCP-1, IL-8 and IL-10, IL-8 and MCP-1, IL-10 and G-CSF, IL-10 and MCP-1, IFN-gamma and MCP-1, MCP-1 and G-CSF, G-CSF and IL-1Ra, and GM-CSF and tumour necrosis factor (TNF)-alpha. Our data indicate that metastatic tumours show desynchronisation of many pathways of induction and synthesis of cytokines that are characteristic of nonmetastatic tumours. FAU - Autenshlyus, Alexander AU - Autenshlyus A AD - 1 Novosibirsk State Medical University, Novosibirsk, Russia. AD - 2 Institute of Molecular Biology and Biophysics, Novosibirsk, Russia. FAU - Arkhipov, Sergey AU - Arkhipov S AD - 1 Novosibirsk State Medical University, Novosibirsk, Russia. AD - 2 Institute of Molecular Biology and Biophysics, Novosibirsk, Russia. FAU - Mikhailova, Elena AU - Mikhailova E AD - 1 Novosibirsk State Medical University, Novosibirsk, Russia. AD - 2 Institute of Molecular Biology and Biophysics, Novosibirsk, Russia. FAU - Marinkin, Igor AU - Marinkin I AD - 1 Novosibirsk State Medical University, Novosibirsk, Russia. FAU - Arkhipova, Valentina AU - Arkhipova V AD - 1 Novosibirsk State Medical University, Novosibirsk, Russia. FAU - Mogilnaya, Ekaterina AU - Mogilnaya E AD - 1 Novosibirsk State Medical University, Novosibirsk, Russia. FAU - Varaksin, Nikolay AU - Varaksin N AD - 3 Joint-Stock Company Vector-Best, Novosibirsk, Russia. FAU - Rukavishnikov, Michael AU - Rukavishnikov M AD - 3 Joint-Stock Company Vector-Best, Novosibirsk, Russia. LA - eng PT - Journal Article DEP - 20170726 PL - England TA - Int J Immunopathol Pharmacol JT - International journal of immunopathology and pharmacology JID - 8911335 RN - 0 (Cytokines) SB - IM MH - Adenocarcinoma/*metabolism/pathology MH - Adult MH - Aged MH - Breast Neoplasms/*metabolism/pathology MH - Cytokines/*biosynthesis MH - Female MH - Humans MH - Lymphatic Metastasis MH - Middle Aged MH - Sentinel Lymph Node/pathology MH - Tumor Microenvironment PMC - PMC5815260 OTO - NOTNLM OT - cytokine OT - cytokine-producing potential OT - mammary adenocarcinoma OT - metastasis into regional lymph nodes OT - polyclonal activators COIS- Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article. EDAT- 2017/07/27 06:00 MHDA- 2018/05/23 06:00 PMCR- 2017/09/01 CRDT- 2017/07/27 06:00 PHST- 2017/07/27 06:00 [pubmed] PHST- 2018/05/23 06:00 [medline] PHST- 2017/07/27 06:00 [entrez] PHST- 2017/09/01 00:00 [pmc-release] AID - 10.1177_0394632017720055 [pii] AID - 10.1177/0394632017720055 [doi] PST - ppublish SO - Int J Immunopathol Pharmacol. 2017 Sep;30(3):308-314. doi: 10.1177/0394632017720055. Epub 2017 Jul 26.